Azole-ResistantAspergillus fumigatusAmong Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H

Azole-resistant (azole-R)Aspergillusis an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk ofAspergilluscolonization and disease due to a favorable lung environment for microorganisms. We performed a nationwide study in 2018 of azole-non-susceptibleAspergillusin CF pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in microbiology 2020-08, Vol.11, Article 1850
Hauptverfasser: Risum, Malene, Hare, Rasmus Kroger, Gertsen, Jan Berg, Kristensen, Lise, Johansen, Helle Krogh, Helweg-Larsen, Jannik, Abou-Chakra, Nissrine, Pressler, Tacjana, Skov, Marianne, Jensen-Fangel, Soren, Arendrup, Maiken Cavling
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Azole-resistant (azole-R)Aspergillusis an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk ofAspergilluscolonization and disease due to a favorable lung environment for microorganisms. We performed a nationwide study in 2018 of azole-non-susceptibleAspergillusin CF patients and compared with data from two prior studies. All airway samples with mold isolates from patients monitored at the two CF centers in Denmark (RH, Jan-Sept and AUH, Jan-Jun) were included. Classical species identification (morphology and thermo-tolerance) was performed and MALDI-TOF/beta-tubulin sequencing was performed if needed. Susceptibility was determined using EUCAST E.Def 10.1, and E.Def 9.3.2.cyp51Asequencing and STRAfgenotyping were performed for azole-non-susceptible isolates and relevant sequential isolates. In total, 340 mold isolates from 159 CF patients were obtained. The most frequent species wereAspergillus fumigatus(266/340, 78.2%) andAspergillus terreus(26/340, 7.6%). Azole-RA. fumigatuswas cultured from 7.3% (10/137) of patients, including 9.5% (9/95) of patients at RH and 2.4% at AUH (1/42), respectively. In a 10-year perspective, azole-non-susceptibility increased numerically among patients at RH (10.5% in 2018 vs 4.5% in 2007-2009). Cyp51A resistance mechanisms were found in nine azole-RA. fumigatusfrom eight CF patients. Five were of environmental origin (TR34/L98H), three were human medicine-driven (two M220K and one M220R), and one was novel (TR343/L98H) and found in a patient who also harbored a TR34/L98H isolate. STRAfgenotyping identified 27 unique genotypes among 45 isolates and >= 2 genotypes in 8 of 12 patients. This included one patient carrying two unique TR34/L98H isolates, a rare phenomenon. Genotyping of sequential TR343/L98H and TR34/L98H isolates from the same patient showed only minor differences in 1/9 markers. Finally, azole-RA. terreuswas found in three patients including two with Cyp51A alterations (M217I and G51A, respectively). Azole-RA. fumigatusis increasing among CF patients in Denmark with the environmentally associated resistance TR34/L98H mechanism being dominant. Mixed infections (wildtype/non-wildtype and several non-wildtypes) and a case of potential additional tandem repeat acquisitionin vivowere found. However, similar genotypes were identified from another patient (and outside this study), potentially suggesting a predominant TR34/L98H clone in DK. These findings suggest an increasing prevalence and c
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2020.01850